Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
 

TTUHSC - USP 800 and Sterile Compounding


The goal of this program is to update on the current guidelines on compounding hazardous sterile drugs, including USP 800.
 
***Please note: this course is 2 hours of CE credit***
 
To access the video after registration, please click the "+" sign to the left of the program title listed below in light blue.

CE Hours

4.00

CE Units

0.400

Activity Type

  • Application

Target Audience(s)

  • Pharmacists
  • Pharmacy Technicians

Accreditation(s)

Accreditation Council for Pharmacy Education
 
Texas Tech University Health Sciencies Center Jerry H. Hodge School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

To receive credit you must watch the recorded webinar and complete the post-test. You must receive a minumum of 70% on the post-test at which time you will be prompted to complete a program evaluation form.
 
 
 

Please choose a Fee Type from the Drop Down Menu Below:
I am a
 

 

   

Objectives

  • Discuss the regulations and organizations involved in the handling of hazardous drugs for sterile compounding.
  • Describe the role of USP <800> in compounding hazardous drugs and topics covered.
  • Identify specific engineering controls specific for hazardous compounding.
  • Differentiate the cleaning processes and aseptic manipulations in BSCs vs. horizontal LAFW.
  • Compare PPE needed for compounding hazardous drugs to non-hazardous compounding
  • Calculate BSA and chemotherapy doses.

Speaker(s)/Author(s)

Mikala Conatser, Pharm.D.


Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation.

Activity Number

0096-0000-21-091-H07-P

Release Date: Sep 21, 2021
Credit Expiration Date: Sep 21, 2024

CE Hours

2.00

Fee

$20.00
   

   

Objectives

  • Discuss the regulations and organizations involved in the handling of hazardous drugs for sterile compounding
  • Describe the role of USP <800> in compounding hazardous drugs and topics covered
  • Identify specific engineering controls specific for hazardous compounding
  • Differentiate the cleaning processes and aseptic manipulations in BSCs vs. horizontal LAFW
  • Compare PPE needed for compounding hazardous drugs to non-hazardous compounding
  • Calculate appropriate volumes for chemotherapy based on given doses.

Speaker(s)/Author(s)

Mikala Conatser, Pharm.D.


Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation.

Activity Number

0096-0000-21-091-H07-T

Release Date: Sep 21, 2021
Credit Expiration Date: Sep 21, 2024

CE Hours

2.00

Fee

$20.00